Segment Reporting

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Segment Reporting

11. Segment Reporting

The Company operates as a single reporting segment, focused on the research and development of cell therapies for patients with autoimmune diseases. The Company's measure of segment profit or loss is net loss. The Chief Executive Officer, as the CODM, manages and allocates resources to the operations of the Company on a total company basis. The Company monitors its cash, cash equivalents, and investments as reported on the Company's Balance Sheets to determine funding for its research and development. The measure of segment assets is reported on the balance sheets as total assets.

As the Company is not yet generating revenue, the CODM evaluates its performance based on progress in pre-clinical and clinical research objectives. Along with the Company’s Statement of Operations and Comprehensive Loss, the CODM regularly reviews budgeted and forecasted expenses to assess liquidity requirements and allocate cash accordingly.

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company's single reporting segment.

A reconciliation to the net loss for the three months ended March 31, 2026 and 2025 is included at the bottom of the table below.

	Three Months Ended March 31,
	2026			2025
Segment expenses:
Personnel related expenses, excluding share-based compensation(1)		8,767		$	15,896
Facilities expenses		4,393			4,565
Direct external development program expenses		7,479			5,420
Other segment expenses(2)		5,999			5,550
Total segment expenses:		26,638			31,431
Segment loss		(26,638	)		(31,431	)
Reconciling items:
Depreciation and amortization		(2,340	)		(2,299	)
Share-based compensation		(1,898	)		(2,834	)
Interest income		2,838			4,376
Other income, net		206			205
Net loss	$	(27,832	)	$	(31,983	)

(1) Personnel related expenses include $5.1 million of severance and other benefits expense for the three months ended March 31, 2025, respectively.

(2) Other segment items include consultants and contractor, lab supplies, and general business expenses.